Literature DB >> 19014790

Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis.

Jeffrey T Jensen1, Anne E Burke, Kurt T Barnhart, Carrie Tillotson, Marci Messerle-Forbes, Dawn Peters.   

Abstract

BACKGROUND: The study was conducted to determine the impact of switching from oral to transdermal patch or vaginal ring contraception on biomarkers of thrombosis. STUDY
DESIGN: Current healthy oral contraceptive (OC) users were randomized to switch to either a contraceptive ring (CR) or patch (CP) and underwent phlebotomy to measure surrogate biomarkers of thrombosis [sex hormone-binding globulin (SHBG), free protein S and activated protein C resistance (APC-r)] before switching, and during the fourth cycle of use of the new method.
RESULTS: Of 142 reproductive age women enrolled, 120 sample pairs were available for analysis. SHBG increased significantly from baseline in CP users [mean change (95% CI), +29.9 nM (9.6-50)] but not in CR users [-1.6 (-16.6 to 13.5)]. Protein S decreased significantly from baseline in CP users [mean change -7.1% (-12.1 to -2.1)], but increased significantly in CR users [+5.3% (1.1-9.6)]. The APC-r ratio did not undergo a significant change from baseline in either group [CP +0.06 (-0.06 to 0.18), CR +0.02 (-0.10 to 0.14)]. Compared to CR users, subjects using the CP had significantly higher SHBG [187.5 (167.0-208), 146 (132.6-159.4), p=.012], significantly lower protein S [81.8 (76.8-86.8), 93.6 (89.1-98.1), p=.001] and similar APC-r ratios [2.99 (2.85-3.14), 3.09 (2.96, 3.22), p=.3] at the Cycle 4 visit.
CONCLUSION: OC users who switch to the ring exhibit beneficial changes in biomarkers of thrombosis, while those switching to the patch display a shift favoring clot formation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19014790      PMCID: PMC2628719          DOI: 10.1016/j.contraception.2008.07.004

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  29 in total

1.  Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.

Authors:  J M Kemmeren; A Algra; D E Grobbee
Journal:  BMJ       Date:  2001-07-21

Review 2.  Oral contraceptives and the risk of venous thrombosis.

Authors:  J P Vandenbroucke; J Rosing; K W Bloemenkamp; S Middeldorp; F M Helmerhorst; B N Bouma; F R Rosendaal
Journal:  N Engl J Med       Date:  2001-05-17       Impact factor: 91.245

3.  Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel.

Authors:  R H Knopp; F E Broyles; M Cheung; K Moore; S Marcovina; W L Chandler
Journal:  Contraception       Date:  2001-01       Impact factor: 3.375

4.  Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?

Authors:  Viveca Odlind; Ian Milsom; Ingemar Persson; Arne Victor
Journal:  Acta Obstet Gynecol Scand       Date:  2002-06       Impact factor: 3.636

5.  Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.

Authors:  C Vasilakis-Scaramozza; H Jick
Journal:  Lancet       Date:  2001-10-27       Impact factor: 79.321

Review 6.  Estrogens, progestogens and thrombosis.

Authors:  F R Rosendaal; A Van Hylckama Vlieg; B C Tanis; F M Helmerhorst
Journal:  J Thromb Haemost       Date:  2003-07       Impact factor: 5.824

7.  Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women.

Authors:  Guido Tans; Astrid van Hylckama Vlieg; M Christella L G D Thomassen; Joyce Curvers; Rogier M Bertina; Jan Rosing; Frits R Rosendaal
Journal:  Br J Haematol       Date:  2003-08       Impact factor: 6.998

Review 8.  Pharmacological profile of progestins.

Authors:  Regine Sitruk-Ware
Journal:  Maturitas       Date:  2004-04-15       Impact factor: 4.342

9.  Sex hormone--binding globulin--a surrogate marker for the prothrombotic effects of combined oral contraceptives.

Authors:  M van Rooijen; A Silveira; A Hamsten; K Bremme
Journal:  Am J Obstet Gynecol       Date:  2004-02       Impact factor: 8.661

Review 10.  Thrombophilia and pregnancy.

Authors:  Michael J Kupferminc
Journal:  Reprod Biol Endocrinol       Date:  2003-11-14       Impact factor: 5.211

View more
  2 in total

Review 1.  Hormonal contraception and thrombotic risk: a multidisciplinary approach.

Authors:  Cameron C Trenor; Richard J Chung; Alan D Michelson; Ellis J Neufeld; Catherine M Gordon; Marc R Laufer; S Jean Emans
Journal:  Pediatrics       Date:  2011-01-03       Impact factor: 7.124

Review 2.  Estrogen and thrombosis: controversies and common sense.

Authors:  Thomas G DeLoughery
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.